Search the Community
Showing results for tags 'cannabidiol'.
Found 2 results
The hemp industry is fighting the DEA again for its right to sell hemp products, including CBD. The Drug Enforcement Agency and US Attorney Generals have spent considerable resources on hemp farmers, state hemp projects, even attacking, raiding and destroying hemp crops in Native American tribal land. Members of congress have joined in the lawsuit against the DEA. Does the DEA even know what it is doing? Why did Eric Holder say hemp was schedule 1, prosecute hemp growers his entire tenure, only to retire and say that the laws should be changed? In Olsen v Holder 2009, some interesting facts about scheduling were reported: DEA Clarifies Status of Hemp in the Federal Register in 2001. What if you are unable to determine from reading the label and from asking the manufacturer or distributor whether the product contains THC? In such circumstances, if you wish to err on the side of caution, you may freely dispose of the product. As stated in the rules that DEA published on October 9, 2001, anyone who has purchased a food or beverage product that contains THC has 120 days (until February 6, 2002) to dispose of the product without penalty under federal law. Wait, Marijuana is the leaves and flowers and hemp is the stalks and seeds? What? Defining “Industrial Hemp”: A Fact Sheet The federal Congressional Research Service issued a report March 2017. Hemp as an Agricultural Commodity Renée Johnson Specialist in Agricultural Policy March 10, 2017 What about Cannabidiol? Since the DEA has been attacking Cannabidiol hemp products, some states have been claiming CBD is illegal. Department of Public Health Position Statement CBD Product Availability in Iowa Nebraska AG issued a memo on Cannabidiol products. Indiana AG issued an opinion of CBD , while the Indiana Governor said stores will have 60 days to destroy or remove CBD products from its stores. The FDA tested some CBD products and found some products contained no CBD, some contained higher than .3% THC and other products fluctuated with percentages of CBD. Also, the FDA has stated that because CBD is being investigated as a new drug, it cannot be marketed as a dietary supplement. The FDA is ignoring history when it says CBD is a "new drug". CBD was an ingredient of Extract of Cannabis, a formulation in the US Pharmacopia dating back to 1851. The fight against hemp, marijuana, cannabis continues. https://mjbizdaily.com/congress-members-defend-cbd-blast-deas-hemp-decision/ Congress members defend CBD, blast DEA’s hemp decision Published January 12, 2018 | By Kristen Nichols In a bold show of support for the hemp industry and CBD, 28 members of Congress are asking a federal appeals court to reject the Drug Enforcement Administration’s argument that cannabidiol is a Schedule 1 drug. The Congress members filed the brief Thursday in conjunction with a pending lawsuit against the DEA. The 9th Circuit Court of Appeals is set to hear arguments in the case Feb. 15. The Congress members – 22 Democrats and six Republicans – argue that the DEA is “blatantly contrary” to the 2014 Farm Bill when it argues that CBD is a marijuana extract and therefore illegal. “The Farm Bill’s definition of industrial hemp includes any part of the plant, including the flower,” the Congress members argue in the brief. The members conclude that the federal agency’s rule about CBD was an “abuse of DEA’s administrative procedure and rulemaking authority.” The lawyer who wrote the brief for the Congress members, Steven Cash, told Marijuana Business Daily that Congress members took the extraordinary step of weighing in on the lawsuit in hopes of seeing the courts resolve the conflict between the Farm Bill and the DEA’s interpretation on the Controlled Substances Act. “Apart from arguing about the relative benefits, flaws and dangers of medical marijuana and hemp, it appears we’re going to solve this (conflict) through traditional avenues, the courts,” Cash said. The DEA said in late 2016 that because CBD cannot be easily extracted from non-flower parts of the cannabis plant, CBD should be considered a controlled substance. The decision brought a hasty lawsuit from the Hemp Industries Association and a CBD business. A lawyer for the hemp companies says the brief will show judges that Congress understood what it was doing when it authorized hemp production, meaning not just the stalks and seeds but the whole plant. “Congress has spoken, yet again,” Bob Hoban said in a statement. “The industrial hemp industry has seen exponential growth … and this case represents the most significant challenge the U.S. hemp industry has seen to date.”
http://www.independent.co.uk/news/health/cannabis-extract-marijuana-psychosis-treatment-mental-health-cbd-thc-cannabidiol-kcl-a8111386.html Psychosis is a mental health diagnosis characterised by hallucinated voices or visions, or delusions where patients have strong and unfounded beliefs, for example feeling there is a conspiracy to harm them. Antipsychotic drugs have been used in treating it for 60 years, but they have limited effectiveness and can have serious side-effects. Professor Philip McGuire, from King’s College London’s Institute of Psychiatry, Psychology and Neuroscience, was the lead author of the study. He said conventional drugs acted by blocking biological receptors for mood-altering chemical dopamine. “However, dopamine is not the only neurotransmitter whose function is altered in psychosis, and in some patients dopamine function may be relatively normal,” he added. “We need new classes of treatment that target different neurotransmitter systems.” This trial found that patients given a CBD treatment saw statistically significant improvements in their psychosis symptoms relative to a group given a placebo. The 83 patients, from the UK, Romania and Poland, also saw significant improvements in their health and severity of their illness as measured by their therapists. There were signs of better cognitive performance as well, but this was not statistically significant. While all the improvements were modest, the patients were still using their antipsychotic medication so it shows CBD treatments can offer additional benefits over and above conventional treatment. The results are published in the American Journal of Psychiatry today. The paper says: “This is, to our knowledge, the first placebo-controlled trial of CBD in schizophrenia. “The data indicate that six weeks of treatment adjunctive to antipsychotic medication was associated with significant effects both on positive psychotic symptoms and on the treating clinicians’ impressions of improvement and illness severity.” Professor McGuire added that larger trials were now needed to confirm these findings in other patient groups. “Although it is still unclear exactly how CBD works, it acts in a different way to antipsychotic medication, and thus could represent a new class of treatment. “Moreover, CBD was not associated with significant side effects. This is also potentially important, as patients may be reluctant to take antipsychotic medication because of concerns about side effects.” https://www.ncbi.nlm.nih.gov/pubmed/29241357 Read the study here. Professor McGuire was singing a different tune about this same study last year. https://www.medscape.com/viewarticle/862312 Lead investigator Philip McGuire, MD, PhD, Department of Psychosis Studies, Institute of Psychiatry Psychology and Neuroscience, Kings College London, United Kingdom, who presented the findings, acknowledged that the improvements with cannabidiol were not dramatic. However, he told Medscape Medical News: "The way I would look at it is that it's quite hard to see an effect in people who are already being treated with something else. Dr Philip McGuire "I would guess that if you didn't have them on antipsychotics, the scope for an improvement would be even greater, because the baseline symptoms would be higher, so it should be easier to show a bigger change." Noting the lengthy discussion of the data that followed his talk, Dr McGuire said: "Somebody in the audience pointed out that there was a previous trial which compared cannabidiol on its own with an antipsychotic and showed that cannabidiol had the same magnitude of effect as an antipsychotic. That shows that the [effect with] monotherapy is at least as big as an antipsychotic." The patients were randomly assigned in a double-blind fashion to cannabidiol 1000 mg/day oral solution, 500 mg twice daily, or matched placebo for 6 weeks and were assessed on intention-to- treat analysis. 1 gram CBD per day. http://alert.psychnews.org/2017/12/cannabidiol-may-be-effective-adjunct-to.html CBD was well tolerated, and rates of adverse events were similar between the CBD and placebo groups. Please always know where your CBD comes from. Have your CBD tested for purity and accurate dosage / strength. https://jamanetwork.com/journals/jama/article-abstract/2661569 There is growing consumer demand for cannabidiol (CBD), a constituent of the cannabis plant, due to its purported medicinal benefits for myriad health conditions. Viscous plant derived extracts, suspended in oil, alcohol (tincture), or vaporization liquid, represent most of the retail market for CBD. Discrepancies between federal and state cannabis laws have resulted in inadequate regulation and oversight, leading to inaccurate labeling of some products. To maximize sampling and ensure representativeness of available products, we examined the label accuracy of CBD products sold online, including identification of present but unlabeled cannabinoids. Read the study here.